Oral Thrush Market: Chemotherapy and Radiotherapy to Fuel the Globally

Pune, India, August, 2022 /press release/- Market Research Future Published a Half-Cooked Research Report on Global Oral Thrush Market Research Report.

The global oral thrush market is expected grow at a CAGR of 5.40% and attain USD 6,614.74 Mn by the end of the forecast period of 2022-2030, as per a research report published by Market Research Future (MRFR). The market has observed continued growth on account of rising prevalence of oral thrush across the globe. Oral thrush is caused by an organism called Candida albicans which occurs naturally in about half of the world's population as a normal oral microbiota, and the disease is developed when Candida albicans is in excess and thus is a very common disease. The rise in chemotherapy and radiotherapy has supported the market growth. Oral thrush becomes quite regular after chemotherapy and radiation and is also common in people who take steroids. Rising prevalence of diabetes also fosters the growth of the market as oral thrush is also common among diabetic patients. Oral thrush is common among women and old people, and a rise in geriatric population boosts the market growth. Smoking too causes oral thrush and rise in smoking population also drives the growth of the market. Neglected hygiene and malnutrition (iron, vitamin B12, folic acid deficiency), especially among under-developed regions of the world is a crucial reason for the rising incidence of oral thrush. Availability of anti-fungal drugs and products and high acceptance of anti-fungal drugs among patients is also propelling the growth of the market. A significant rise in initiatives towards the education of oral health care and inducing awareness about the available treatment options provide impetus to market growth. Factors such as lack of awareness, loss of patent and growth of generics are expected to hinder the growth of the market over the forecast period.

Segmentation

The global oral thrush market has been segmented based on type, diagnosis, treatment, and end user. By, type, the market has been segmented into pseudomembranous, erythematous, hyperplastic, and others. By diagnosis, the market has been segmented into examination, biopsy, endoscopy, and others. By treatment, the market has been segmented into anti-fungal, immune-modulators, and others. By end-user, the market has been segmented into hospitals & clinics, academic and research, and others.

Explore In-depth Details: Oral Thrush Market Research Report

Regional Analysis

The key markets of the global oral thrush market include the Americas, Europe, Asia Pacific and the Middle East & Africa. The Americas account for the largest share of the market owing to high expenditure on healthcare, early adoption of new products, and concentration of major healthcare companies in the region. Europe is the second largest market after the Americas due to rising awareness of oral health care, increased expenditure on healthcare and increased R&D activities in the region. Countries such as Germany and France lead the Europe market while the UK is expected to be the fastest growing market in the region. Asia Pacific is poised to grow rapidly and is likely to be led by China and India due to growing healthcare sector in the region and the presence of a vast patient population in the region. South East Asian countries such as Thailand, Vietnam, and Malaysia are expected to emerge as key contributors over the forecast period. The Middle East & Africa market is expected to exhibit limited but steady growth. Gulf nations are expected to contribute chiefly to the market growth. The African region is expected to exhibit moderate growth, however, the region offers lucrative growth opportunities due to the large unmet medical needs of the region.

Competitive Landscape

The notable players of the global oral thrush market include Bayer AG, Stellar Pharma, Wockhardt Ltd., Bristol Laboratories, GlaxoSmithKline Plc., Teva Pharmaceuticals, Pfizer Inc., Ranbaxy Laboratories Limited, Glenmark Pharmaceuticals, and others.